Trials / Completed
CompletedNCT02323685
Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)
Single Escalating-dose, Open-label Study to Assess the Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) After Acute Aneurysmal Subarachnoid Hemorrhage (SAH)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Prolong Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Safety and effect of SANGUINATE on patients DCI following SAH.
Detailed description
The purpose of this study is to study the safety and effect of SANGUINATE on patients suffering from delayed cerebral ischemia after acute aneurysmal subarachnoid hemorrhage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SANGUINATE™ | Single infusion of SANGUINATE (pegylated carboxyhemogloblin) |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2016-06-01
- Completion
- 2016-10-01
- First posted
- 2014-12-23
- Last updated
- 2016-10-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02323685. Inclusion in this directory is not an endorsement.